MedTrace Logo

Trial of JYB1904 in Chronic Spontaneous Urticaria.

NCT06509334 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2024-11-29

No results posted yet for this study

Summary

This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.

Conditions

Interventions

DRUG

JYB1904

Participants will receive JYB1904 at week0 and receive placebo at week4,8,12

DRUG

JYB1904

Participants will receive JYB1904 at week0,8 and receive placebo at week4,12

DRUG

Omalizumab

Participants will receive Omalizumab every 4 weeks for 12 weeks

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-04
Primary Completion
2026-07-15
Completion
2026-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06509334 on ClinicalTrials.gov